-
Media ReleaseFDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
-
Media ReleaseNovartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media ReleaseNovartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
-
Media ReleaseNovartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
-
Media ReleaseNovartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
-
Media ReleaseNovartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
-
Media ReleaseFDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
-
Media ReleaseImportant Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
-
Media ReleaseNovartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
-
Media ReleaseLonger-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
-
Media ReleaseNovartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media ReleaseNew “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers